Abstract
A series of patients with esophageal cancer was treated with chemotherapeutic regimens of the new antitumor platinum preparation nedaplatin plus 5-FU in combination with radiation therapy, and the therapeutic responses, side effects, and complications were clinically assessed. There were 2 patients with a complete response and 11 patients with a partial response, hence, a response rate of 76.5%. Major adverse reactions were those of hematological toxicity and included leukopenia (13 patients, 76.5%), thrombocytopenia (8 patients, 47.1%), and lowered serum hemoglobin concentration (9 patients, 52.9%). The leukopenia and thrombocytopenia, though of a grade 3 severity in 3 and 2 patients, respectively, subsided spontaneously in all affected cases. Gastrointestinal adverse reactions were mild and included appetite loss in 7 patients (41.2%) and nausea in 2 patients (11.8%). The only abnormality in renal function observed was a slight elevation of serum creatinine in one patient. The combined therapy of chemotherapy with nedaplatin and 5-FU plus radiation produced a high response rate in the treatment of carcinoma of the esophagus and was associated with reduced gastrointestinal and renal toxicity. The results indicate the combined therapy with nedaplatin to be clinically useful.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Orringer MB, Forastiere AA, Perez-Tamayo C, Urba SG, Takasugi BJ, Bromberg J. Chemotherapy and radiation therapy before transhiatal esophagectomy for esophageal carcinoma. Ann Thorac Surg 1990; 49: 348–55.
Naunheim KS, Petruska PJ, Roy TS, Andrus CH, Johnson FE, Schlueter JM, et al. Preoperative chemotherapy and radiotherapy for esophageal carcinoma. J Thorac Cardiovasc Surg 1992; 103: 887–95.
Adelstein DJ, Rice TW, Tefft M, Koka A, Van Kirk MA, Kirby TJ, et al. Aggressive concurrent chemoradiotherapy and surgical resection for proximal esophageal squamous cell carcinoma. Cancer 1994; 74: 1680–5.
Apinop C, Puttisak N, Preeha N. A prospective study of combined therapy in esophageal cancer. Hepato Gastroenterol 1994; 391–3.
Mercke C, Albertson M, Hambraeus G, Tennvall J, Lillo-Gill R, Samuelsson L, et al. Cisplatin and 5-FU combined with radiotherapy and surgery in the treatment of squamous cell carcinoma of the esophagus, palliative effects and tumor response. Acta Oncol 1991; 30: 617–22.
Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitevcius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Eng J Med 1992; 326: 1593–8.
Prise EL, Etienne PL, Meunier B, Maddern G, Hassel MB, Gedouin D, et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994; 73: 1779–84.
Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, et al: Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC375101D) administrated by 5-day continuous intravenous infusion. Cancer Res 1991; 51: 1472–7.
Fukuda M, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, et al. Phase II study of (glycolate-0,0’) diammineplatinum (II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 1990; 26: 393–6.
Akaza H, Togashi M, Nishio Y, Miki T, Kotake T, Matsumura Y, et al. Phase II study of cis-di-ammine(glycolato)platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. Cancer Chemother Phamacol 1992; 31: 187–92.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649–55.
International Union Against Cancer: TNM Classification of Malignant Tumors. Hermanek P, Sobin LH, ed. 4th fully revised ed. Berlin: Springer Verlag, 1987; 37–42.
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981; 47: 207–14.
Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K, et al: Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol 1993; 23: 250–7.
Yamanaka H, Hiramatsu Y, Kawaguchi Y, Kojima Y, Hioki K, Yamamoto M. Surgical treatment for poor-risk patients with carcinoma of the esophagus. Jpn J Surg 1991; 21: 178–83.
Yamanaka H, Hiramatsu Y, Kojima Y, Kawaguchi Y, Hioki K. Usefulness of catecholamine preparations in the postoperative management of esophageal carcinoma. Asian J Surg 1992; 15: 103–8.
Imamura M, Shimada Y, Kanda Y, Fukumoto M, Yanagibashi K, Miyahara T, et al. Usefulness of preoperative low dose cisplatin treatment for advanced esophageal cancer. Surgery Today 1992; 22: 09–15.
Iizuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: A Japanese esophageal oncology group trial. Jpn J Clin Oncol 1992; 22: 172–6.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yamanaka, H., Motohiro, T., Michiura, T. et al. Nedaplatin and 5-FU combined with radiation in the treatment for esophageal cancer. Jpn J Thorac Caridovasc Surg 46, 943–948 (1998). https://doi.org/10.1007/BF03217851
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03217851